Focused On-demand Library for Transcriptional enhancer factor TEF-1

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P28347

UPID:
TEAD1_HUMAN

ALTERNATIVE NAMES:
NTEF-1; Protein GT-IIC; TEA domain family member 1; Transcription factor 13

ALTERNATIVE UPACC:
P28347; A4FUP2; E7EV65

BACKGROUND:
The protein Transcriptional enhancer factor TEF-1, with alternative names such as NTEF-1 and Protein GT-IIC, is integral to the Hippo signaling pathway, which is essential for regulating organ size and suppressing tumors. It achieves this by controlling the kinase cascade that restricts proliferation and promotes apoptosis, specifically through the phosphorylation and inactivation of YAP1 and WWTR1/TAZ. TEF-1's ability to bind to specific enhansons and activate transcription highlights its critical function in cellular processes, including cell proliferation and migration.

THERAPEUTIC SIGNIFICANCE:
Given TEF-1's critical role in Sveinsson chorioretinal atrophy, a disease marked by specific retinal and choroidal lesions, it represents a promising target for developing novel therapeutic approaches. Understanding the role of TEF-1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.